Fourteen-Day Evolution of COVID-19 Symptoms during the Third Wave in Nonvaccinated Subjects and Effects of Hesperidin Therapy: A Randomized, Double-Blinded, Placebo-Controlled Study

COVID-19 symptoms can cause substantial disability, yet no therapy can currently reduce their frequency or duration. We conducted a double-blind placebo-controlled trial of hesperidin 1000 mg once daily for 14 days in 216 symptomatic nonvaccinated COVID-19 subjects. Thirteen symptoms were recorded a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dupuis, Jocelyn, Laurin, Pierre, Tardif, Jean-Claude, Hausermann, Leslie, Rosa, Camille, Guertin, Marie-Claude, Thibaudeau, Karen, Gagnon, Lyne, Cesari, Frank, Robitaille, Martin, Moran, John E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649310/
https://www.ncbi.nlm.nih.gov/pubmed/36387348
http://dx.doi.org/10.1155/2022/3125662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649310/
https://www.ncbi.nlm.nih.gov/pubmed/36387348
http://dx.doi.org/10.1155/2022/3125662

Ejemplares similares